2025
Long-Term Outcomes and Risk Factors of Mortality After Reoperation on the Aortic Root: A Single-Center 20-Year Experience
Bozini N, Piber N, Vitanova K, Sideris K, Herold U, Guenzinger R, Georgescu T, Amabile A, Krane M, Prinzing A. Long-Term Outcomes and Risk Factors of Mortality After Reoperation on the Aortic Root: A Single-Center 20-Year Experience. Journal Of Clinical Medicine 2025, 14: 3727. PMID: 40507487, PMCID: PMC12155750, DOI: 10.3390/jcm14113727.Peer-Reviewed Original ResearchAortic root reoperationNon-elective surgeryTemporary mechanical circulatory supportAortic rootMechanical circulatory supportRoot reoperationConcomitant proceduresProlonged cardiopulmonary bypass timeAssociated with worse survivalRisk factorsCirculatory supportCardiopulmonary bypass timeRisk factors of mortalityBaseline patient riskHigh-volume centersTranscatheter aortic valve implantationReceiver operating characteristic curveLong-term outcomesPredictors of mortalityFactors of mortalityHigh-risk procedureAortic valve implantationYears of ageBypass timeEuroSCORE IIProgressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 2025, 10: 104105. PMID: 39813824, PMCID: PMC11783098, DOI: 10.1016/j.esmoop.2024.104105.Peer-Reviewed Original ResearchConceptsClear-cell renal cell carcinomaAdvanced clear-cell renal cell carcinomaNK cell phenotypeNK cell functionNK cellsRenal cell carcinomaClinical outcomesCell carcinomaCell phenotypeRestoration of NK cell functionNormal kidneyNatural killer (NK) cellsMarkers of tissue residencyNatural killer cell dysfunctionAssociated with worse overall survivalClear-cell renal cell carcinoma patientsLocalized clear-cell renal cell carcinomaTumor-infiltrating NK cellsAnalyzed single-cell RNA sequencing dataAssociated with worse survivalExpression of cytotoxic genesPaired normal kidneyLocal tumor extensionNK cell subsetsPrimary tumor specimensA Perspective on the MARS2 Trial
Lim E, Opitz I, Woodard G, Bueno R, de Perrot M, Flores R, Gill R, Jablons D, Pass H. A Perspective on the MARS2 Trial. Journal Of Thoracic Oncology 2025, 20: 262-272. PMID: 39772349, DOI: 10.1016/j.jtho.2024.12.014.Peer-Reviewed Original ResearchConceptsPleural mesotheliomaPleurectomy decorticationTrial interpretationAssemble individualsAssociated with worse survivalPhase 3 randomized controlled trialsTime of randomizationTeam leadersResectable PMHistological subtypesPreoperative stagingWorse survivalSurgical mortalityConsensus guidelinesTeamAdverse eventsFacilitationChemotherapyPayer's willingnessSurgical communityTrialsSurgeryMesotheliomaQuality assuranceDecortication
2024
Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis
Ghosh H, Patel R, Claus E, Castro L, Wen P, Ligon K, Meredith D, Bi W. Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. Neuro-Oncology 2024, 27: 993-1003. PMID: 39584448, PMCID: PMC12083226, DOI: 10.1093/neuonc/noae258.Peer-Reviewed Original ResearchFocal gene amplificationsCDKN2A/B lossFocal amplificationGene amplificationAssociated with worse survivalAssociated with reduced survivalGrade 4 casesGrade 4 patientsLoss of CDKN2A/BMolecular featuresOverall survival predictionIntermediate prognosisTumor gradeWorse survivalIDH1/2-mutantShorter survivalHistological criteriaStratify riskPoor outcomeHistological featuresCDKN2A/BHomozygous lossAcademic medical centerGrade 2Glioma diagnosticsClinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
Getz T, Kewan T, Bewersdorf J, Stempel J, Lanino L, Wei W, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Ball S, Chandhok N, Logothetis C, Bidikian A, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta M, Komrokji R, Zeidan A. Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database. Blood 2024, 144: 3219-3219. DOI: 10.1182/blood-2024-202075.Peer-Reviewed Original ResearchNon-complex karyotypeInternational Prognostic Scoring SystemCytogenetic risk groupHMA initiationComplex karyotypeIPSS-RHypomethylating agentsOverall survivalRisk groupsCytogenetic abnormalitiesAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationAssociated with worse survivalHypomethylating agent combinationsPoor-risk cytogeneticsPeripheral blood blastsTreated with azacitidinePrognostic scoring systemMeasured overall survivalStem cell transplantationKaplan-Meier methodLog-rank testOutcomes of PTTime-to-event analysisRisk of patientsIncidence of bacterial blood stream infections in patients with acute GVHD
Wallis W, Gulbis A, Wang T, Lee C, Sharma A, Williams K, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem M, MacMillan M, Kitko C, Pidala J, Spellman S, Lee S, Alousi A. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplantation 2024, 60: 52-57. PMID: 39420192, PMCID: PMC11724748, DOI: 10.1038/s41409-024-02426-9.Peer-Reviewed Original ResearchBacterial bloodstream infectionsHematopoietic stem cell transplantationAcute GVHDNon-relapse mortalityGrade II-IV acute GVHDAllogeneic hematopoietic stem cell transplantationGrade III/IV acute GVHDBacterial blood stream infectionsAssociated with worse survivalStem cell transplantationBlood stream infectionsHigh-risk populationGVHD treatmentNeutrophil engraftmentBloodstream infectionsWorse survivalCell transplantationGI involvementOrgan involvementPost-transplantationPost-engraftmentRisk populationHigh riskPatientsGVHDDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.Peer-Reviewed Original ResearchConceptsCTLA-4 expression levelsCancer-associated fibroblastsAssociated with worse survivalExpression of immune checkpointsLAG-3 expressionDesmoplastic melanomaLymphoid aggregatesCTLA-4PD-1Immune checkpointsIntratumoral leukocytesLAG-3Tumor compartmentsWorse survivalCD20+B cellsIncreased expression of immune checkpointsProgrammed cell death protein 1Macrophage/monocyte markerSentinel lymph node positivityCell death protein 1Associated with poor prognosisLymph node positivityDense fibrous stromaPotential prognostic significanceCore of tumorsMulti-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, Manyam G, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli M, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray J, Herbst R, Wistuba I, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee J, Zhang J, Haymaker C. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clinical Cancer Research 2024, 30: 1655-1668. PMID: 38277235, PMCID: PMC11016892, DOI: 10.1158/1078-0432.ccr-23-0251.Peer-Reviewed Original ResearchConceptsChromosome copy-number variationsOverall survivalMultiplex immunofluorescenceMulti-omics analysisAssociated with superior progression-free survivalNCounter PanCancer Immune Profiling PanelSquamous cell lung cancer patientsSuperior progression-free survivalTreated with nivolumab monotherapyAssociated with worse overall survivalNon-small cell carcinomaAssociated with worse survivalCell lung cancer patientsCold immune microenvironmentProgression-free survivalImmune Profiling PanelRegulatory T cellsPhase III trialsResponse to ICIImmune cell infiltrationHigher immune scoresImmune cell densityLung cancer patientsWhole-exome sequencingImmune gene expression profilesDefining the Role of Extrachromosomal DNA Amplifications in Medulloblastoma.
Zhao D, Verhaak R. Defining the Role of Extrachromosomal DNA Amplifications in Medulloblastoma. Cancer Research 2024, 84: 515-516. PMID: 38175761, DOI: 10.1158/0008-5472.can-23-4025.Peer-Reviewed Original ResearchConceptsCell-to-cell variabilityWhole-genome sequencingCircular extrachromosomal DNACRISPRi experimentsRewiring eventsExtrachromosomal DNAMultiomics sequencingExtrachromosomal DNA amplificationsCopy numberEcDNADNA amplificationAssociated with worse survivalOncogene amplificationSequenceAmplificationWorse survivalPatient cohortTumor heterogeneityIntratumoral heterogeneityCRISPRiMedulloblastomaPatient outcomesDNA
2023
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patients
2022
Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.Peer-Reviewed Original ResearchIDH-wt GBMAssociated with poor OSMethylation subclassesOverall survivalPoor OSIDH-wtMolecular subclassesRTK IAssociated with worse survivalAssociated with OSIDH-wildtype glioblastomaPotential survival benefitAssociation of hyperglycemiaAverage glucose valuesAverage glucoseStupp protocolDexamethasone doseMGMT statusSurvival benefitWorse survivalMesenchymal tumorsPerformance statusLow glucose levelsMGMT methylationMolecular subtypes
2021
NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Placantonakis D, Possemato R, Snuderl M. NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi154-vi154. PMCID: PMC8598635, DOI: 10.1093/neuonc/noab196.602.Peer-Reviewed Original ResearchIDH-wt glioblastomaAssociated with poor OSMethylation subclassesDexamethasone doseOverall survivalPoor OSIDH-wtMolecular subclassesAssociated with worse survivalRNA expressionIDH-wildtype glioblastomaPotential survival benefitDNA methylation clustersIsocitrate dehydrogenase (IDH)-wildtypeAssociated with survivalClinical next-generation sequencingPlasma glucose measurementsDNA methylation studiesAverage glucoseNext-generation sequencingStupp protocolMGMT statusMesenchymal tumorsPrognostic significanceSurvival benefit
2018
Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations
Narayan R, Creasy J, Goldman D, Gönen M, Kandoth C, Kundra R, Solit D, Askan G, Klimstra D, Basturk O, Allen P, Balachandran V, D’Angelica M, DeMatteo R, Drebin J, Kingham T, Simpson A, Abou‐Alfa G, Harding J, O’Reilly E, Butte J, Matsuyama R, Endo I, Jarnagin W. Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations. Cancer 2018, 125: 575-585. PMID: 30427539, PMCID: PMC6636637, DOI: 10.1002/cncr.31850.Peer-Reviewed Original ResearchConceptsGallbladder cancer pathogenesisErb-b2 receptor tyrosine kinase 3Gallbladder cancerJapanese patientsSMAD family member 4Overall survivalTumor mutationsAT-rich interactive domain 2Associated with worse survivalPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaAT-rich interactive domain 1AMedian mutational burdenCause of cancer deathKaplan-Meier methodKruskal-Wallis tests assessed differencesTime of surgeryTyrosine kinase 3Cancer-associated genesCatalytic subunit alphaMulti-institutional comparisonsTests assessed differencesPrimary tumorClinicopathological variablesWorse survivalMutational burdenObstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial
Dahdaleh F, Sherman S, Poli E, Vigneswaran J, Polite B, Sharma M, Catenacci D, Maron S, Turaga K. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surgery 2018, 164: 1223-1229. PMID: 30297240, DOI: 10.1016/j.surg.2018.06.044.Peer-Reviewed Original ResearchConceptsStage III colon cancerIII colon cancerDisease-free survivalColon cancerAdjuvant chemotherapyWorse survivalHistological gradeN stageCycles of adjuvant chemotherapyMedian follow-up timeAssociated with worse survivalChemotherapy-only armHigh-risk featuresAssociated with recurrenceKaplan-Meier methodIndependent risk factorCohort of patientsFollow-up timeMultivariate survival analysisCox proportional hazards modelsLong-term outcomesFisher's exact testRisk stratification modelBody mass indexProportional hazards model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply